“FGFR Inhibitor Shows Promising Results in Intrahepatic Cholangiocarcinoma Patients: FOENIX-CCA2 Trial Published in NEJM”

2023-05-17 12:16:20

In the FOENIX-CCA2 trial, 42% of previously treated patients with intrahepatic cholangiocarcinoma had FGFR2fusion or rearrangement following treatment with the FGFR inhibitor futibatinib. The results were recently published in The New England Journal of Medicine.

More information is only accessible to subscribers who have prescribing authority.

Login

NB: To see all information you need an account to log in. Are you already logged in? Then you do not have sufficient rights to view this information. Do you want to adjust your account? Then click here